<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608606</url>
  </required_header>
  <id_info>
    <org_study_id>FKoral-sl</org_study_id>
    <nct_id>NCT02608606</nct_id>
  </id_info>
  <brief_title>Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors</brief_title>
  <acronym>FKosl</acronym>
  <official_title>Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After liver transplantation one of the most important cost, for both patients and their
      health insurance system, is immunosuppressive drug therapy. Tacrolimus (FK 506) is considered
      the cornerstone of immunosuppressive therapy in solid organ transplantation. Oral
      administration is the usual route, however, sublingual (SL) administration has been recently
      reported. This method of administration avoids first pass metabolism and allows an
      alternative route after transplant surgery, particularly in those patients who should extend
      the period of fasting (prolonged intubation, ileus, etc). Interestingly, in some studies, the
      dose of tacrolimus SL required to maintain similar plasma concentrations compared with oral
      administration, is significantly lower, even up to 50%, which can result in considerable
      savings in short and long term. Among these studies, only one was conducted in liver
      recipients. This study suggest that SL administration of tacrolimus could allow to obtain
      similar concentrations compared with oral administration. The design of this study did not
      assess the existence of differences in the dose required and only included six patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient will be scheduled fasting to liver transplant unit where the pharmacokinetic
      study was performed. After installation of the venous needle, blood samples will be collected
      on 4 ml tubes with EDTA as an anticoagulant at the following intervals of time in hours: 0
      (immediately before the oral administration of tacrolimus); 0.5; 1.0; 1.5; 2; 4; 6; 9 and 12
      h. post-dose. Once the blood samples taken, the tubes will be plugged, invest gently to mix
      with anticoagulant and stored at -20 ° C until analysis.

      Subsequently, tacrolimus administration was change to sublingual route and dose was adjusted
      to obtain similar trough levels to those determined on per oral administration. The capsule
      be opened and its contents shall be deposited in the sublingual mucosa. To be ensure that
      drug will be absorted the patient will be instructed to insistently that after sublingual
      placement of the drug, should not swallow the capsule content for at least 15 minutes. The
      same pharmacokinetic study described for the oral route will be performed.

      Breakfast will be administered 2 hours after ingesting the drug and lunch and dinner 6 and 10
      hours after respectively. Fluid intake is discretionary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare tacrolimus exposure using per oral and sublingual administration employing AUC (Area Under the Curve).</measure>
    <time_frame>30 days</time_frame>
    <description>compared oral administration versus sublingual administration of tacrolimus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare tacrolimus dose necessary to obtain similar trough levels employing per oral and sublingual administration</measure>
    <time_frame>30 days</time_frame>
    <description>compared oral administration versus sublingual administration of tacrolimus</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <condition>Effects of Immunosuppressant Therapy</condition>
  <arm_group>
    <arm_group_label>oral administration of tacrolimus</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sublingual administration of tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>compared oral administration versus sublingual administration of tacrolimus.</description>
    <arm_group_label>sublingual administration of tacrolimus</arm_group_label>
    <other_name>FK506</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outline of immunosuppression that includes tacrolimus dosing every 12 hours.

          -  Stable plasma levels of tacrolimus in 3 consecutive measurements.

          -  Stable blood tests: biochemical profile, creatinine and liver profile.

          -  Absence of treatment with drugs that have interaction with tacrolimus (antifungal and
             diltiazem) and use of grapefruit juice.

          -  Absence of active bacterial or viral infection and rejection episodes within 8 weeks
             prior.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Benitez, Hepatologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <results_reference>
    <citation>Agopian VG, Petrowsky H, Kaldas FM, Zarrinpar A, Farmer DG, Yersiz H, Holt C, Harlander-Locke M, Hong JC, Rana AR, Venick R, McDiarmid SV, Goldstein LI, Durazo F, Saab S, Han S, Xia V, Hiatt JR, Busuttil RW. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg. 2013 Sep;258(3):409-21. doi: 10.1097/SLA.0b013e3182a15db4.</citation>
    <PMID>24022434</PMID>
  </results_reference>
  <results_reference>
    <citation>Rabkin JM, Corless CL, Rosen HR, Olyaei AJ. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation. Transplant Proc. 2001 Feb-Mar;33(1-2):1532-4.</citation>
    <PMID>11267411</PMID>
  </results_reference>
  <results_reference>
    <citation>Collin C, Boussaud V, Lefeuvre S, Amrein C, Glouzman AS, Havard L, Billaud EM, Guillemain R. Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. Transplant Proc. 2010 Dec;42(10):4331-7. doi: 10.1016/j.transproceed.2010.09.126.</citation>
    <PMID>21168693</PMID>
  </results_reference>
  <results_reference>
    <citation>Reams BD, Palmer SM. Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. Am J Respir Med. 2002;1(2):91-8. Review.</citation>
    <PMID>14720063</PMID>
  </results_reference>
  <results_reference>
    <citation>Reams D, Rea J, Davis D, Palmer S. Utility of sublingual tacrolimus in cystic fibrosis patients after lung transplantation. J Heart Lung Transplant. 2001 Feb;20(2):207-208.</citation>
    <PMID>11250374</PMID>
  </results_reference>
  <results_reference>
    <citation>Romero I, Jiménez C, Gil F, Escuin F, Ramirez E, Fudio S, Borobia A, Carcas A. Sublingual administration of tacrolimus in a renal transplant patient. J Clin Pharm Ther. 2008 Feb;33(1):87-9. doi: 10.1111/j.1365-2710.2008.00884.x.</citation>
    <PMID>18211623</PMID>
  </results_reference>
  <results_reference>
    <citation>Srinarong P, Pham BT, Holen M, van der Plas A, Schellekens RC, Hinrichs WL, Frijlink HW. Preparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administration. Drug Dev Ind Pharm. 2012 Apr;38(4):490-500. doi: 10.3109/03639045.2011.613075. Epub 2011 Sep 30.</citation>
    <PMID>21961909</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsapepas D, Saal S, Benkert S, Levine D, Delfin M, Cremers S, Amann S, Dadhania D, Kapur S, Aull M. Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. Pharmacotherapy. 2013 Jan;33(1):31-7. doi: 10.1002/phar.1149.</citation>
    <PMID>23307542</PMID>
  </results_reference>
  <results_reference>
    <citation>van de Plas A, Dackus J, Christiaans MH, Stolk LM, van Hooff JP, Neef C. A pilot study on sublingual administration of tacrolimus. Transpl Int. 2009 Mar;22(3):358-9. doi: 10.1111/j.1432-2277.2008.00779.x. Epub 2008 Oct 30.</citation>
    <PMID>18980626</PMID>
  </results_reference>
  <results_reference>
    <citation>Watkins KD, Boettger RF, Hanger KM, Leard LE, Golden JA, Hoopes CW, Singer JP. Use of sublingual tacrolimus in lung transplant recipients. J Heart Lung Transplant. 2012 Feb;31(2):127-32. doi: 10.1016/j.healun.2011.10.015. Epub 2011 Dec 16.</citation>
    <PMID>22177691</PMID>
  </results_reference>
  <results_reference>
    <citation>Nasiri-Toosi Z, Dashti-Khavidaki S, Nasiri-Toosi M, Khalili H, Jafarian A, Irajian H, Abdollahi A, Sadrai S. Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. Exp Clin Transplant. 2012 Dec;10(6):586-91. doi: 10.6002/ect.2012.0032. Epub 2012 Jul 5.</citation>
    <PMID>22770208</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The preliminary data from this trial will be presented at the AASLD Liver meeting in San Francisco in November 2015</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

